View by Specialty

Trending

PC0924Houry_Graphic_01_WEB
September 11, 2024
4 min read
Save

CDC data reveal three social drivers that influence suicide risk

Cardiometabolic Disorders News

SPONSORED CONTENT
Save
SPONSORED CONTENT
August 20, 2024
2 min read
Save

Tirzepatide cuts risk for progression to type 2 diabetes for adults with prediabetes

Tirzepatide cuts risk for progression to type 2 diabetes for adults with prediabetes

Adults with prediabetes and overweight or obesity have a 94% lower risk for developing type 2 diabetes with the once-weekly GIP/GLP-1 dual agonist tirzepatide vs. placebo, according to top-line results from the SURMOUNT-1 3-year study.

SPONSORED CONTENT
August 20, 2024
2 min read
Save

Levels of some circulating proteins may inform care of comorbid obesity, heart failure

Levels of some circulating proteins may inform care of comorbid obesity, heart failure

Twelve circulating proteins associated with obesity and heart failure may inform treatment for adults with both conditions, according to a study published in Obesity.

Trending

PC0924Houry_Graphic_01_WEB
September 11, 2024
4 min read
Save

CDC data reveal three social drivers that influence suicide risk

SPONSORED CONTENT
August 15, 2024
4 min read
Save

Medicare announces price cuts for 10 drugs in first round of drug price negotiations

Medicare announces price cuts for 10 drugs in first round of drug price negotiations

The Centers for Medicare & Medicaid Services announced lower Medicare Part D prices for 10 drugs that will take effect in 2026, according to a press release.

SPONSORED CONTENT
August 14, 2024
2 min read
Save

Adults with type 2 diabetes improve HbA1c, medication use with pharmacist referral

Adults with type 2 diabetes improve HbA1c, medication use with pharmacist referral

Adults with type 2 diabetes who are referred to a clinical pharmacist are more likely to meet their HbA1c goal and receive appropriate medication management of comorbidities than people receiving usual care, according to a presenter.

SPONSORED CONTENT
August 13, 2024
2 min read
Save

Top-line data show significant weight loss with HU6 in patients with obesity-related HFpEF

Top-line data show significant weight loss with HU6 in patients with obesity-related HFpEF

HU6, a controlled metabolic accelerator, met the primary endpoint of weight reduction in patients with obesity-related heart failure with preserved ejection fraction, according to top-line results of the phase 2a HuMAIN trial.

SPONSORED CONTENT
August 12, 2024
2 min read
Save

Kidney, CV outcomes similar for SGLT2 inhibition vs. GLP-1s for diabetes

Kidney, CV outcomes similar for SGLT2 inhibition vs. GLP-1s for diabetes

SGLT2 inhibitors were associated with similar renal and CV outcomes vs. GLP-1 receptor agonists for patients with diabetes, regardless of chronic kidney disease status, researchers reported.

SPONSORED CONTENT
August 12, 2024
2 min read
Save

SGLT2 inhibitors greatly underprescribed in patients who qualify for them

SGLT2 inhibitors greatly underprescribed in patients who qualify for them

In an analysis of more than 3 million U.S. adults, most patients with a class 1a recommendation for SGLT2 inhibitors were not prescribed them, researchers reported in the Journal of the American College of Cardiology.

SPONSORED CONTENT
August 12, 2024
2 min read
Save

GLP-1 use tied to lower risk for hyperkalemia than DPP-IV therapy in type 2 diabetes

GLP-1 use tied to lower risk for hyperkalemia than DPP-IV therapy in type 2 diabetes

Adults with type 2 diabetes using a GLP-1 receptor agonist are less likely to develop hyperkalemia than those using a DPP-IV inhibitor, according to a study published in JAMA Internal Medicine.

SPONSORED CONTENT
August 12, 2024
2 min read
Save

Tirzepatide linked to lower risk for death, adverse CV and kidney outcomes vs. GLP-1s

Tirzepatide linked to lower risk for death, adverse CV and kidney outcomes vs. GLP-1s

Adults with type 2 diabetes have lower risks for death and major adverse cardiovascular and kidney events if they use tirzepatide compared with GLP-1 receptor agonists, according to observational data published in JAMA Network Open.

SPONSORED CONTENT
August 08, 2024
2 min read
Save

Adults maintain drops in body weight, HbA1c at 1 year after duodenal mucosal resurfacing

Adults maintain drops in body weight, HbA1c at 1 year after duodenal mucosal resurfacing

Adults with obesity and type 2 diabetes had reductions in body weight and HbA1c 1 year after undergoing an endoscopic procedure that resurfaces the duodenum lining, according to top-line results from a real-world registry study.

View more
Healio Minute Subscribe to Healio Minute emails You're now subscribed to Healio Minute Emails
Healio Minute Subscribe to Healio Minute emails You're now subscribed to Healio Minute Emails